Company intelligence / Profile preview

Kolltan Pharmaceuticals

New Haven, Connecticut, United Statesir.celldex.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 1

Overview

The company had initiated clinical trials for its first drug while developing a substantial pipeline of other programs. KTN3379 (anti-ErbB3) was in Phase 1b trials with plans for Phase 2, and KTN0158 (anti-KIT) had begun Phase 1 trials before acquisition.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

CDX-0158

Phase 1

Indications: Gastrointestinal stromal tumors

1 more asset in the full pipeline.

Request access →

Partnerships

MedImmune

Beyond the preview

Go deeper on Kolltan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kolltan Pharmaceuticals.

Explore the full profile